Host a Marketing Presentation

Product Theaters are turnkey, 45-minute marketing presentations about your company’s products or services. These sessions do not offer CME credit; rather, they give industry supporters the freedom to create a presentation centered on their company’s products. 

Product Theater

Please use the DDW Mobile App or DDW Online Planner for final times and locations. Product Theaters will be available to view on demand starting June 10.

Eligibility

Only DDW industry supporters who have secured exhibit space or participating in the virtual event are eligible to apply for a Product Theater (PT) slot, subject to availability and adherence to all published guidelines. In the event a company reserves an exhibit space but cancels prior to DDW or is a no-show on the exhibit floor, permission to hold the product theater will be revoked. This policy will be strictly enforced, no refunds will be given, and any violation will result in the loss of priority points earned for DDW 2022 for the supporting company. Product Theaters for 2022 are currently sold out.

Rules and Regulations

Product theaters are limited and will be assigned by DDW on a first-come, first-served basis. View the available times.

The fee for one time slot is $25,000. Companies are eligible to secure more than one time slot.

All DDW Product Theaters and Marketing Opportunities will be billed at 100% upon selection and execution of the application and sponsorship contracts. Payment is due no later than 30 days from the date of order. Failure to make full payment by this date will result in the item being placed back into inventory for another party to purchase and Product Theater organizers will incur cancellation fees for the Product Theater fee (see below). All payments are non-refundable after Jan. 21, 2022. DDW reserves the right to reject or resell any opportunity if payment is not received within 30 days. If an order is placed after Jan. 31, 2022, payment will be due upon reservation. DDW reserves the right to not fulfil any unpaid Marketing Opportunities. Space will be assigned only after full payment has been received based on availability at that time.

Notification of product theaters must be in writing. Any supporter canceling a product theater will be charged a fee based on the following schedule:

  • On or before Feb. 14, 2022: 50% of total fee is due, regardless of whether the slot is re-sold.
  • After Feb. 14, 2022: 100% of total fee is due, regardless of whether the slot is re-sold. Product Theater cancellations will result in automatic cancellation of any marketing opportunities secured for the Product Theater. No refunds will be provided for these other opportunities.

The sponsoring company shall be solely responsible for the management of the logistics of their PT, and for payment of additional costs related to the PT including but not limited to catering, electrical, internet, etc. DDW does not provide logistical support for product theaters apart from those services specifically listed below.

Freeman AV is the exclusive provider of audio-visual services. Expenses for additional services and additional electrical costs incurred are the responsibility of the sponsoring company. Any additional equipment needed must be approved by DDW and items must not alter the setup of the product theater in any way. Added items will need to be added for the entire day as not to impactor disturb other product theaters or activities scheduled in this space.

The following AV is included:

  • Two lavaliere microphones.
  • One podium microphone.
  • One wired aisle microphone.
  • Two 70 monitors
  • Sound amplification and mixer system.
  • VGA switcher.
  • Electricity for the above.

Lead retrieval will not be provided. If you wish to collect leads from your product theater, it is your responsibility to coordinate.

The product theater area must be cleared within 45 minutes of the end of each presentation.

If you wish to have a hybrid or virtual component for your Product Theater, it is your responsibility to coordinate. DDW will place a listing within the virtual platform and on DDW.org. Supporters will be responsible for providing the link to the hybrid or virtual Product Theater or recording. Link to your meeting room, website or recording will be due to DDW by April 15, 2022. If you record your on-site or virtual Product Theater, DDW will host your recording on DDW.org through Aug. 31, 2022. More information will be provided once a contract is submitted.

  • Assign day and time.
  • Upon request, provide a complimentary mailing list of pre-registered attendees.
  • List the Product Theater in the DDW mobile app, DDW.org, DDW virtual platform and DDW Online Planner (if PT is reserved by March 17, 2022).
  • Theater in DDW Exhibit Hall that will seat up to 100 people.
  • Day of push notifications on the mobile app.
  • Industry Supporter Showcase poster.

Pre-Meeting Policies

  • All products and services discussed at DDW shall be related to digestive health or GI practice and to DDW’s mission and must be of professional or educational benefit or interest to meeting participants.
  • Programs may NOT offer CME credit.
  • Promotional and marketing materials: All promotional and marketing materials must be approved by DDW prior to distribution. It is the sole responsibility of the sponsor to work with DDW to receive approval of materials.
  • 50 words or less of promotional copy, for use in the DDW Online Planner, DDW Mobile App and other official DDW materials, is due March 17, 2022. Failure to provide content by this date will result in DDW only listing the topic and sponsoring organization on all published materials. DDW will not alter any signage or other published materials after this date.

On-Site Policies: Posters and Flyers

Posters or flyers may be displayed and distributed in the following locations only:

  • The exhibiting company’s booth
  • Outside the Product Theater (posters only and must be within five feet of the theater)
  • Industry Showcase Area
  • Symposia Central Area

  • All material must contain the following statement: "The Product Theater content and views expressed therein are those of the sponsor and not of Digestive Disease Week®."
  • The DDW logo may not be used in any promotions, advertisements, meeting materials or correspondence related to the program.

  • Application deadline: March 17, 2022
  • Payment: Jan. 31, 2022
  • Faculty list: March 17, 2022
  • Title: March 17, 2022
  • 50 word description: March 17, 2022
  • Educational tracks (Choose up to 3): March 17, 2022
  • Link to virtual component or recording: April 15, 2022

Supporters are encouraged to provide catering at their own expense for the participants attending the Product Theater. If the supporter is providing food and beverage for your Product Theater, it is your responsibility to order porter service to clean the area for the next group. It is the supporter's responsibility to ensure the area is cleared quickly at the end of your session. Supporters will ensure that attendees and speakers have cleared the area immediately after the event.

The supporting company and affiliates shall indemnify DDW and its components societies against all claims, demands, actions, expenses, damages, penalties, attorney’s fees, or proceedings incurred by DDW because of the publications distributed at, statements made during or any other conduct arising out of or in any way connected with the Product Theater.

The Product Theater area will not be secured. DDW will not be liable for damage or loss to the supporting company's property, nor shall DDW be liable for any injury that may occur in the area.

Failure to comply with any of these rules will result in the loss of priority points earned for DDW 2022 for the exhibiting company.

The following schedule is as of May 11, 2022. Please use the DDW Mobile App or DDW Online Planner for final times and locations.

  • May 22
  • May 23
  • May 24

Sunday, May 22, 2022

9:30 a.m.Ferring Pharmaceuticals, Inc.
The Power of the Microbiome-Can it be unlocked to break the cycle of recurrent Clostridioides difficile infection (CDI)
9:30–10:15 a.m.
DDW Theater 1 - Hall B2
This program will discuss the role of the microbiome in overall health and explore the relationship between the gut microbiome and CDI.
10:30 a.m.STERIS Endoscopy
Liquid Nitrogen Cryotherapy in the Endoscopic Management of Barrett’s Esophagus & Esophageal Neoplasia: Updates, Current Controversies and Challenges
10:30 a.m.–11:15 a.m.
DDW Theater 2 - Hall F2
11:30 a.m.AbbVie
UC Powerful Evidence
11:30 a.m.–12:15 p.m.
DDW Theater 1 - Hall B2
12:30 p.m.AbbVie
Advancing Care for Crohn's Disease
12:30–1:15 p.m.
DDW Theater 2 - Hall F2
Speaker: Anita Afzali, MD, MPH, FACG, AGAF, Medical Director, OSU IBD Center, Ohio State Inflammatory Bowel Disease Center, Hilliard, OH.
1:30 p.m.Takeda
From Diagnosis to Treatment: Assessing Moderately to Severely Active Crohn’s Disease
1:30–2:15 p.m.
DDW Theater 1 - Hall B2
Anita Adzali, MD will present an interactive case study discussing a hypothetical Crohn’s disease patient. This presentation will discuss patient presentation, biomarker and endoscopy findings, treatment options, and follow-up.
2:30 p.m.EndoGastric Solutions
TIF 2.0 - Changing the GERD Paradigm
2:30–3:15 p.m.
DDW Theater 1 - Hall B2
The TIF 2.0 procedure using the EsophyX Z+ device is shaping future GERD treatment. During this presentation, innovators will discuss the latest clinical results and how TIF 2.0 can be used in a broader spectrum of patient populations.
Janssen Biotech, Inc.
Optimizing Biologic-Naïve Patient* Outcomes in Crohn’s Disease with STELARA® (ustekinumab) *In adults with moderately to severely active Crohn's disease
2:30–3:15 p.m.
DDW Theater 2 - Hall F2
Please visit Booth 3526 for Product Theater details.
Speakers: Bincy Abraham, MD, MS and Stephen B. Hanauer, MD
3:30 p.m.Gilead Sciences, Inc.
Hepatitis D Virus Infection: Epidemiology, Pathophysiology, and Clinical Management
3:30–4:15 p.m.
DDW Theater 1 - Hall B2
This informative presentation provides clinicians with an in-depth review of hepatitis delta virus (HDV), the most severe form of chronic viral hepatitis. Topics covered will include its global prevalence, relationship with hepatitis B virus, progression to advanced liver disease, and who to screen for HDV.
Bristol Myers Squibb
Another Day is Dawning in the Control of UC: ZEPOSIA (Ozanimod), A Once-Daily Oral Therapy
3:30–4:15 p.m.
DDW Theater 2 - Hall F2
Join us for a program where gastroenterologist Dr. Amar Naik and neurologist Dr. Barry Hendin will provide an overview of the clinical profile of ZEPOSIA, the first and only sphingosine 1-phosphate receptor modulator (S1P) for the treatment of moderately to severely active ulcerative colitis, with first approval in relapsing multiple sclerosis (MS).

Monday, May 23, 2022

9:30 a.m.Bristol Myers Squibb
Patient Identification and Treatment of Adult Patients with Moderately to Severely Active UC with ZEPOSIA (Ozanimod)
9:30–10:15 a.m.
DDW Theater 1 - Hall B2
Join us for an overview of the efficacy and safety profile of ZEPOSIA and a conversation with Dr. Miguel Regueiro on patient identification and treatment considerations for your patients with moderately to severely active UC.
Speaker: Dr. Miguel Regueiro, MD.
10:30 a.m.AbbVie and Ironwood
A Proactive Way to Treat IBS-D: Post-Marketing Information and Phase 4 Data
10:30–11:15 a.m.
DDW Theater 2 - Hall F2
Please join us in a clinical review of Phase 4 data and the latest post-marketing information on a proactive treatment that may help your IBS-D patients. IBS-D is a chronic functional GI disorder that affects approximately 16 million people.
Speaker: Darren Brenner, MD
11:30 a.m.AbbVie
Could It Be More Than Occasional Constipation? Time to Have a Deeper Conversation with Your Adult Patients with IBS-C
11:30 a.m.–12:15 p.m.
DDW Theater 1 - Hall B2
IBS-C impacts nearly 11.5 million Americans. It’s a chronic condition that is characterized by constipation, and burdensome symptoms like abdominal pain, bloating and discomfort. Research shows many patients are uncomfortable discussing the totality of their symptoms with their healthcare provider. Join this clinical review to learn more about a treatment that may help adults with IBS-C.
12:30 p.m.Phathom Pharmaceuticals
Unmet Needs in the Treatment of Acid-related Disorders
12:30–1:15 p.m.
DDW Theater 2 - Hall F2
Phathom Pharmaceuticals, a biopharmaceutical company focusing on novel treatments for GI disorders, is excited to host Colin Howden, MD, GRCP, emeritus professor at the University of Tennessee, to discuss unmet needs in the treatment of acid-related disorders.
1:30 p.m.Medtronic
Medtronic Innovation Updates for Bleeding Management
1:30–2:15 p.m.
DDW Theater 1 - Hall B2
This presentation will highlight a new topical powder for endoscopic hemostasis, Nexpowder™. Learn more about this new technology and hear from experts about their clinical experience in managing active bleeding and preventing delayed bleeding in nonvariceal upper GI bleeding. Join us to gain insights into what’s next in nonvariceal UGIB management.
2:30 p.m.Regeneron and Sanofi Genzyme
Eosinophilic Esophagitis: A Clinical Perspective of Type 2 Inflammation
2:30–3:15 p.m.
DDW Theater 1 - Hall B2
EoE is a progressive, local manifestation of underlying systemic Type 2 inflammation, resulting in substantial QoL impairment. In this presentaion, an expert will discuss the effects of an uncontrolled immune response, Type 2 inflammation, on the esophagus and explain the coexisting nature of Type 2 diseases in patients with EoE.
Ardelyx
An Innovative Approach to the Treatment of Adults with Irritable Bowel Syndrome with Constipation (IBS-C)
2:30–3:15 p.m.
DDW Theater 2 - Hall F2
Please join us for an engaging session where Dr. Brooks Cash and Dr. Mark Pimentel will discuss an innovative approach to treat adults with irritable bowel syndrome with constipation (IBS-C).
3:30 p.m.Intercept Pharmaceuticals, Inc.
3:30–4:15 p.m.
DDW Theater 1 - Hall B2
Kris V. Kowdley, MD, will give an informative presentation about taking the treatment of Primary Biliary Cholangitis (PBC) a step further. Learn about an approved treatment for patients with PBC.
Janssen Biotech, Inc.
STELARA®: Data-Driven Outcomes in Ulcerative Colitis (UC) Biologic-naïve Patients* *For adults with moderately to severely active ulcerative colitis
3:30–4:15 p.m.
DDW Theater 2 - Hall F2
Please visit Booth 3526 for Product Theater details.
Speakers: Miguel Regueiro, MD and Anita Afzali, MD, MPH

Tuesday, May 24, 2022

9:30 a.m.Castle Biosciences
The Role of TissueCypher in the Management of Barrett’s Esophagus.
9:30–10:15 a.m.
DDW Theater 1 - Hall B2
Learn how a precision medicine test can analyze esophageal biopsies and other clinical risk factors to inform your Barrett’s esophagus patient management. Understand how this prognostic test – supported extensively by published clinical evidence – can assess individual risk of progression to HGD and EAC and easily integrate into your care pathway.
10:30 a.m.GlaxoSmithKline
Exploring Cholestatic Pruritus in PBC — Are We Even Scratching the Surface?
10:30–11:15 a.m.
DDW Theater 2 - Hall F2
Cholestatic pruritus is a serious, chronic condition that adversely impacts the sleep, quality of life, and emotional well-being of people living with PBC. This presentation will discuss how cholestatic itch can be identified and a patient-centric approach to management of cholestatic pruritus.
11:30 a.m.Madrigal Pharmaceuticals
Emerging Concepts in Nonalcoholic Steatohepatitis (NASH)
11:30 a.m.–12:15 p.m.
DDW Theater 1 - Hall B2
This session will explore several emerging NASH concepts, including epidemiology and comorbidities, pathophysiology and the role of lipotoxicity in the liver and patient identification and monitoring approaches.
12:30 p.m.Fractyl Health
The Duodenum: A New Therapeutic Horizon for Metabolic Disease
12:30–1:15 p.m.
DDW Theater 2 - Hall F2
The prevalence and overlap of metabolic diseases including T2D and NAFLD highlights common pathophysiology. Increased dietary sugar and fat consumption contributes to duodenal dysfunction which may potentiate disease progression. This session will discuss the duodenal mucosa as a metabolic regulator and investigational therapy that targets the mucosa for metabolic disease.
1:30 p.m.Eli Lilly
Gut Decision - Bowel Urgency in Ulcerative Colitis
1:30–2:15 p.m.
DDW Theater 1 - Hall B2
Which ulcerative colitis (UC) symptom may impact your patients’ lives the most? Explore this important topic with Dr. Bincy Abraham as she discusses bowel urgency’s true impact on patients through new study data, proposed mechanism of bowel urgency in UC, and a case study.
2:30 p.m.Eli Lilly
Beyond the Gut: The Science of Wellness in Inflammatory Bowel Disease
2:30–3:15 p.m.
DDW Theater 2 - Hall F2
This educational symposium will explore the evidence behind the role of positive interventions that improve resilience in patients with IBD.

Related Opportunities

Satellite Symposia

Industry Supporters can host educational programs before or after DDW scientific sessions.
ICWs are meetings and events arranged by exhibitors, third party planners, educational institutions or other non-profit organizations during DDW.

In-Conjunction With Meetings

ICWs are meetings and events arranged by exhibitors, third-party planners, educational institutions or other non-profit organizations during DDW.
Two women at computer in Exhibit Hall

Industry Supporter Prospectus

The prospectus provides details you need to know to reserve your space at DDW 2022.